Advertisement

Topics

SU2C/Amgen Company Profile

20:16 EDT 25th September 2017 | BioPortfolio


News Articles [500 Associated News Articles listed on BioPortfolio]

Stand Up To Cancer, Genentech Launch 2nd Round of Catalyst Grants

Stand Up To Cancer is launching its second SU2C Catalyst™ collaboration in 6 months with Genentech, a member of the Roche Group, with the goal of accelerating development of new cancer treatments an...

Stand Up To Cancer, Genentech to Fund 2nd Round of Catalyst Grants

Stand Up To Cancer is launching its second SU2C Catalyst™ collaboration in 6 months with Genentech, a member of the Roche Group, with the goal of accelerating development of new cancer treatments an...

New SU2C-Lustgarten Foundation team aims to apply CAR T-cell therapy to pancreatic cancer

(American Association for Cancer Research) Stand Up To Cancer is supporting a new translational research team to explore how a type of immunotherapy that has been very successful in blood cancers can ...

Syngene expands Amgen collaboration as it recovers from fire incident

Syngene International is doubling the footprint of its research and development center following an expanded research collaboration with Amgen Inc. The Indian contract research organization inaugurate...

Amgen Remains A Standout Among Biotechs

Amgen's Repatha is believed to have potential sales of $2 billion by 2020

Amgen To Present At The UBS Global Life Sciences Conference

THOUSAND OAKS, Calif., May 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, May 21, 2013, at the Sheraton New York Times Square...

Amgen up as Xgeva closes in on expanded indication

US biotech Amgen closed 1.6% up on Monday at $165.09 after news of further progress relating to its monoclonal…

Amgen-Aktie: Eines der besten Signale überhaupt - Chartanalyse

Düsseldorf - Amgen-Chartanalyse von HSBC Trinkaus & Burkhardt: Die Analysten von HSBC Trinkaus & Burkhardt nehmen in einer aktuellen Aktienanalyse die Aktie des Biotechkonzerns Amgen Inc. (ISIN: US.....

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Nplate [Amgen Inc]

These highlights do not include all the information needed to use Nplate safely and effectively. See full prescribing information for Nplate. Nplate (romiplostim)For subcutaneous injection Initial U.S...

Neulasta [AMGEN INC]

These highlights do not include all the information needed to use Neulasta safely and effectively. See full prescribing information for Neulasta. Neulasta (pegfilgrastim) injection, for subcutaneous u...

Neulasta [Physicians Total Care, Inc.]

These highlights do not include all the information needed to use Neulasta safely and effectively. See full prescribing information for Neulasta.Neulasta (pegfilgrastim) injection, for subcutaneous us...

Sensipar [Amgen, Inc]

These highlights do not include all the information needed to use Sensipar safely and effectively. See full prescribing information for Sensipar. Sensipar (cinacalcet) TabletsInitial U.S. Approval: 20...

Xgeva [AMGEN]

These highlights do not include all the information needed to use XGEVA™ safely and effectively. See full prescribing information for XGEVA. Xgeva (denosumab)injection, for subcutaneous useInitial U...

PubMed Articles [4 Associated PubMed Articles listed on BioPortfolio]

Letter--The Authors Respond.

None of the authors of this study are involved in financial or personal relationships with agencies, institutions, or organizations that inappropriately influenced the statistical analysis plan or int...

Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method.

The expression and tissue distribution of RANK (Receptor Activator of Nuclear Factor κ B) and RANK Ligand (RANKL) are of critical interest in relation to efficacy and safety of antibodies against RAN...

Patent trend and competitive analysis of cancer immunotherapy in the United States.

Immunotherapy has brought high hopes for cancer treatment, and attracted tremendous resources from the biopharmaceutical community. Here we analyze cancer immunotherapy-related patents granted by the ...

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

As part of its single technology appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clini...

Clinical Trials [16 Associated Clinical Trials listed on BioPortfolio]

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen,) based on maintenance of hemoglobin (Hb) levels and s...

An Open Label Treatment Extension Study of AMG 706

This is an extension study to provide ongoing treatment with AMG 706 monotherapy for subjects with solid tumors who have completed the planned duration of AMG 706 treatment on a separate A...

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

The purpose of this study is to assess the safety, tolerability, and utility of AMG 531 unit dosing (µg) in thrombocytopenic subjects with ITP.

Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation

The purpose of this study is to collect local laboratory data on immunoreactive parathyroid hormone (iPTH), calcium and phosphorus levels and estimated glomerular filtration rate (GFR) at ...

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

5-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation. EPOCH: Etoposide, VP-16, NSC-141540; Prednisone, PRED, NSC-10023; Vincristine, VCR, NSC-67574; Cyclophosphamide, CTX...

Companies [46 Associated Companies listed on BioPortfolio]

SU2C/Amgen

Amgen, Inc.

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bri...

Amgen Inc.

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bri...

Amgen

The Amgen Foundation (www.amgen.com/citizenship/overview.html) seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live...

Amgen AB

Amgen är ett världsledande bioteknologiskt läkemedelsföretag. Genom vetenskapliga upptäckter och innovationer har företaget under 25 års tid bidragit till att radikalt förbättra människors l...

More Information about "SU2C/Amgen" on BioPortfolio

We have published hundreds of SU2C/Amgen news stories on BioPortfolio along with dozens of SU2C/Amgen Clinical Trials and PubMed Articles about SU2C/Amgen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SU2C/Amgen Companies in our database. You can also find out about relevant SU2C/Amgen Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record